• SCOTUS to issue a decision on mifepristone in the coming months

    March 27, 2024 - The Supreme Court of the United States (SCOTUS) has yet to decide on mifepristone access in the US; however, many predict that the decision will come by late spring, June or July 2024 at the latest. Public opinion also predicts that the justices will side with the FDA on this decision, based on the rhetoric throughout the hearings. On Tuesday,...

  • AstraZeneca acquires Fusion Pharmaceuticals in $2 billion deal

    March 20, 2024 - On March 19, 2024, AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals in a $2 billion deal. Through this deal, AstraZeneca will expand its portfolio and gain access to Fusion’s clinical-stage, next-generation radioconjugates and research that have been used in oncology treatments. According to the American...

  • Eli Lilly partners with Amazon Pharmacy to deliver GLP-1 drugs

    March 15, 2024 - Amazon Pharmacy will now be filling prescriptions for glucagon-like peptide-1 (GLP-1) drugs — and other pharmaceuticals for obesity, diabetes, and migraines — requested through Eli Lilly’s LillyDirect platform, according to an announcement by Lilly on March 13, 2024. The pharmacy will join TruePill as one of the platform’s...

  • Acne treatments contain harmful levels of benzoyl peroxide

    March 13, 2024 - On March 6, 2024, Valisure, an independent quality assurance lab, issued a press release identifying harmfully high levels of benzoyl peroxide in multiple skincare products, specifically products marketed for acne. The press release notes that at high levels, benzoyl peroxide can form into benzene, an established human carcinogen, at concentrations...


Today's Top Stories

FDA issues warning letters for unapproved topical pain relief products

On March 26, 2024, the United States FDA published a press release informing consumers of six warning letters sent to companies regarding unauthorized topical pain relief products. The following...

SCOTUS to issue a decision on mifepristone in the coming months

The Supreme Court of the United States (SCOTUS) has yet to decide on mifepristone access in the US; however, many predict that the decision will come by late spring, June or July 2024 at the latest....

Age-adjusted drug overdose deaths stabilized from 2021 to 2022

A CDC analysis noted that between 2021 and 2022, the age-adjusted rate of drug overdose deaths did not change significantly, a variation from previous years where the rates climbed overall. However,...

AstraZeneca acquires Fusion Pharmaceuticals in $2 billion deal

On March 19, 2024, AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals in a $2 billion deal. Through this deal, AstraZeneca will expand its portfolio and gain access to...

FDA ODAC favors 2 CAR T-cell therapies for multiple myeloma

A meeting of the United States FDA Oncologic Drugs Advisory Committee (ODAC) voted to expand the approval of Abecma and Carvykti, two types of chimeric antigen receptor (CAR) T-cell therapies, for...

Eli Lilly partners with Amazon Pharmacy to deliver GLP-1 drugs

Amazon Pharmacy will now be filling prescriptions for glucagon-like peptide-1 (GLP-1) drugs — and other pharmaceuticals for obesity, diabetes, and migraines — requested through Eli...

FDA requests $7.2 billion from Biden’s 2025 fiscal year budget

On March 11, 2024, the United States FDA issued a press release announcing its request for $7.2 billion from the president’s fiscal year (FY) 2025 budget, increasing its FY 2023 request by 7.4%...

View all stories